Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Programmed cell death protein-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors activate the immune system against cancer.
• Tumor mutational burden and PD-1/PD-L1 expression levels predict response to these inhibitors.
• Improving response rates to PD-1/PD-L1 inhibitors remains a critical area of research.

Observation:

• A patient with metastatic bladder cancer exhibited primary resistance to PD-1/PD-L1 inhibitor therapy.
• The patient subsequently developed a cytomegalovirus (CMV) infection.

Findings:

• Following the cytomegalovirus infection, the patient achieved a complete response to the previously ineffective PD-1/PD-L1 inhibitor treatment.
• This suggests a potential link between CMV infection and restored sensitivity to immune checkpoint blockade.

Implications:

• Cytomegalovirus infection may overcome primary resistance to PD-1/PD-L1 inhibitors in certain cancers.
• Further investigation into the mechanisms underlying this phenomenon could lead to novel therapeutic strategies.
• This case highlights the complex interplay between viral infections and cancer immunotherapy.